NEWS

Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process

February 22, 2021

Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has engaged a leading international contract development and manufacturing organization ("CDMO") to synt

Read More

Mindset Pharma Added to North American Psychedelics Index

February 19, 2021

Toronto, Ontario--(Newsfile Corp. - February 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that effective today, it has been added to the North American Psychedelics Index which is provided by German-bas

Read More

Mindset Announces Milestone in New Drug Program with Successful Proof-of-Concept Animal Studies of Its Patent-Pending Psilocybin-Inspired Drug Candidates

February 10, 2021

Toronto, Ontario--(Newsfile Corp. - February 10, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that several of its proprietary, novel and diverse psychedelic compounds are demonstrating strong potency and e

Read More

Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds

February 5, 2021

Toronto, Ontario--(Newsfile Corp. - February 5, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a leading drug discovery and development company focused on the development novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce that the Company has filed 3 final patent applications with the U.S. Patent and Trademark Offi

Read More

Mindset Selects Compounds from Its Third Psilocybin-Inspired Drug Family to Move into in vivo PoC Studies

February 1, 2021

Toronto, Ontario--(Newsfile Corp. - February 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has selected a subset of representative compounds belonging to its proprietary third family of patent-pe

Read More

Mindset Pharma Announces Listing on the Frankfurt Stock Exchange

January 27, 2021

Toronto, Ontario--(Newsfile Corp. - January 27, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that its common shares have been accepted for listing on the Frankfurt Stock Exchange (the "FSE") and commenced t

Read More

Mindset Pharma to Present at Inaugural KCSA Psychedelic Investor Conference

January 20, 2021

Toronto, Ontario--(Newsfile Corp. - January 20, 2021) - Mindset Pharma Inc. (CSE:MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has been invited to present at the inaugural KCSA Psychedelic Investor Conference being held on Tuesday, January 26, 2021

Read More

Mindset Pharma Invited to Present at Upcoming Canaccord Genuity Mental Health Conference

January 14, 2021

Toronto, Ontario--(Newsfile Corp. - January 14, 2021) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce it has been invited to present at the Canaccord Genuity conference "New Paradigms & Treatment Approaches in Mental Health", being he

Read More

Mindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of Potential Clinical Use Cases Including Micro-Dosing

January 6, 2021

Toronto, Ontario--(Newsfile Corp. - January 6, 2021) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that certain compounds belonging to its third fam

Read More

Mindset Engages Hybrid Financial Inc.

December 31, 2020

Toronto, Ontario--(Newsfile Corp. - December 31, 2020) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that the Company has entered into an arm's-len

Read More

Mindset Further Expands Portfolio of Psychedelic Drug Candidates with Third U.S. Provisional Patent Application; 50 Total New Psychedelic Patent-Pending Compounds Synthesized

December 29, 2020

Toronto, Ontario--(Newsfile Corp. - December 29, 2020) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines and related technologies for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has filed another provisional patent ap

Read More

Mindset Pharma to Commence Trading on the CSE on December 23, 2020 Under the Symbol "MSET"

December 22, 2020

Toronto, Ontario--(Newsfile Corp. - December 22, 2020) - Mindset Pharma Inc. (CSE: MSET) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that the common shares of the Company will commence trading on the Canad

Read More

Mindset Pharma Announces Closing of Non-Brokered Private Placement, Increasing Aggregate Gross Proceeds Raised to $5,000,000

December 16, 2020

Toronto, Ontario--(Newsfile Corp. - December 16, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has closed an additional non-brokered private placement, pursuant to which t

Read More

Mindset Pharma Announces Upsizing and Closing of $4.17 Million Brokered Private Placement Financing

December 15, 2020

Toronto, Ontario--(Newsfile Corp. - December 15, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has upsized and completed its previously announced brokered private placemen

Read More

Mindset Pharma Closes Ontario Brain Institute Funding and Announces Private Placement Offering

November 9, 2020

Toronto, Ontario--(Newsfile Corp. - November 9, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that it has entered into a secured convertible promissory note transaction with the

Read More

Mindset Pharma Commences In Vivo Program for Its Proprietary Next Generation Psychedelic Drug Candidates and Provides Corporate Update

October 20, 2020

Toronto, Ontario--(Newsfile Corp. - October 20, 2020) - Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery and development company at the forefront of the evolving psychedelics space, today announced that it has begun confirmatory in-vivo studies with InterVivo Solutions Inc. ("InterVivo Solutions") to further profile the efficacy, safety and pharmacological properties of Mindset's

Read More

Mindset Pharma Inc. and North Sur Complete Combination; North Sur Changes Name to Mindset Pharma Inc.

September 15, 2020

Vancouver, British Columbia--(Newsfile Corp. - September 15, 2020) - Mindset Pharma Inc. (formerly, North Sur Resources Inc.) (the "Company") is pleased to announce that it has completed its previously announced business combination with Mindset Pharma Inc. ("Mindset"). The business combination was carried out pursuant to the terms of a share exchange agreement (the "Share Exchange Agreement") da

Read More

Mindset Pharma Announces Promising Test Results of its Novel and Proprietary Psilocybin-Inspired Compounds

August 31, 2020

TORONTO, Aug. 31, 2020 -- Mindset Pharma ("Mindset"), a leading drug discovery and development business focused on next-generation psychedelic medicines to treat neuropsychiatric indications with unmet needs, announces today the preliminary screening results of certain patent-pending compounds.

Read More

Mindset Pharma Announces Filing of Groundbreaking Psilocybin Synthesis Patent

July 27, 2020

TORONTO, July 27, 2020 (GLOBE NEWSWIRE) -- Mindset Pharma (“Mindset”), a leading drug discovery business focused on developing next-generation psychedelic medicines, announces today the filing of a provisional patent application with the USPTO for a groundbreaking process to synthesize psilocybin and psilocin—two of the known active compounds in psychedelic mushrooms.

Read More

North Sur Resources and Mindset Pharma Announce Proposed Transaction to Accelerate Development of Medical Psychedelics Industry

June 29, 2020

Vancouver, British Columbia – (June 29, 2020) – North Sur Resources Inc. (“North Sur”) and Mindset Pharma Inc. (“Mindset”) are pleased to announce that they have signed a binding letter of intent (the “Letter of Intent”) to combine their corporate entities. Mindset is an Ontario-based psychedelic pharma company that has filed multiple patents for new, pharmacologically optimized psychedelic medici

Read More

Mindset Pharma Synthesizes Second Generation Medicinal Psychedelic Compounds

May 6, 2020

Toronto, Ontario--(Newsfile Corp. - May 6, 2020) - Mindset Pharma ("Mindset"), a leading drug discovery business focused on developing next-generation psychedelic medicines, announced today that it has successfully synthesized approximately one-quarter of the target compounds identified in its previously filed patent applications, with another quarter of the compounds in late stages of synthesis.

Read More

Mindset Pharma Begins Work with Leading R&D Contractor for Next-Generation Psychedelic Drugs

April 14, 2020

TORONTO, April 14, 2020 /CNW/ - Mindset Pharma ("Mindset"), a leading drug discovery business focused exclusively on novel and best in class psychedelics, announced today that preclinical work has begun on the novel psychedelics identified in Mindset's provisional patent applications filed earlier this year. Mindset has identified multiple novel compound structures that the Mindset scientific team

Read More

Mindset Completes Private Placement Financing

February 14, 2020

Mindset Pharma Inc. (“Mindset” or the “Company”) is pleased to announce that it has completed an equity financing for total proceeds of $704,835. Mr. Richard Patricio, founder and Director of Mindset Pharma commented, “Interest in the psychedelic space has exploded since we formed Mindset in mid- 2019. Our business plan remains to create an IP portfolio of novel psychedelic com

Read More

Mindset Pharma engages InterVivo Solutions for Initial Drug Analysis

February 10, 2020

Mindset Pharma Inc. (“Mindset” or the “Company”) announced today that it has executed a Master Laboratory Services Agreement (the “MLSA”) with InterVivo Solutions Inc. (“InterVivo”). Based in Fergus, Ontario, InterVivo is a specialty preclinical contract research organization which develops and provides translational animal models and transformative research services in an effort to improve the cl

Read More

Mindset Pharma Files Groundbreaking Psychedelic Patents

February 4, 2020

Mindset Pharma Inc. (“Mindset” or the “Company”) announced today that it has filed a number of provisional patent applications with the United States Patent and Trademark Office. These patent applications cover a comprehensive range of psychedelic compounds, and their related processing, potential compositions, and therapeutic uses.

Read More